Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Recruiting 2Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 1397Neoplasms 1129Prostatic Neoplasms 744Lung Neoplasms 619Colorectal Neoplasms 596Carcinoma, Non-Small-Cell Lung 569Carcinoma, Hepatocellular 413Pancreatic Neoplasms 402Leukemia, Myeloid, Acute 398Stomach Neoplasms 355Multiple Myeloma 326Brain Neoplasms 311Ovarian Neoplasms 309Head and Neck Neoplasms 289Neoplasm Metastasis 273Precursor Cell Lymphoblastic Leukemia-Lymphoma 260Rectal Neoplasms 253Uterine Cervical Neoplasms 248Recurrence 248Melanoma 242Esophageal Neoplasms 237Glioblastoma 232Squamous Cell Carcinoma of Head and Neck 231Lymphoma 213Sarcoma 207Urinary Bladder Neoplasms 192Colonic Neoplasms 192Glioma 191Triple Negative Breast Neoplasms 188Hematologic Neoplasms 183

Interventions

olaparib 1decitabine and cedazuridine drug combination 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × OTHER × BRCA1 Mutation × Clear all
NCT06177171 2026-05-27

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

University of California, San Francisco

Phase 1 Recruiting
18 enrolled

BRCA1 Mutation

NCT05420064 2025-11-12

An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results

Memorial Sloan Kettering Cancer Center

Phase NA Recruiting
1,000 enrolled

BRCA1 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡